Millions of people worldwide suffer from inherited non-malignant blood disorders like thalassaemia and sickle cell disease. The culprit: genetic defects in their blood stem cells.
One of the novel therapies for thalassaemia that has stood out recently has undoubtedly been the first and only, one-time, groundbreaking gene therapy for transfusion dependent β-thalassaemia ZYNTEGLO by Bluebird Bio that gives patients the potential to reach complete transfusion independence.
As part of our advocacy efforts that aim to help facilitate and support patients‘ access to Gene Therapy and other New and Innovative Therapies for the treatment of thalassaemia, we are conducting a quick online survey on gene therapy to gather and assess your own perspectives and views on this important matter!
Take TIF’s survey today and give your voice power! 💪📢
To make this easier for you, we prepared the survey in the following 8 languages: